Primary Biliary Cholangitis Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Size, Share & Trends, Drivers, Restraints, Opportunities, Manufacturer, Applications, And Segments

  • AMR-1064826
  • May 2021
  • Pharmaceuticals
  • 121 Pages
The Primary Biliary Cholangitis Market research report comprises of an overall in depth-analysis such as market drivers, opportunities, restraints, latest developments and trends, segmentation of the market, competitive analysis, global as well as regional analysis by showcasing how each of these factors can improve the further growth of the market on an overall perspective. The report also showcases the overall market value which includes the historic data (2018-2019) and forecast data (2020-2028) generated through the revenue (USD Mn)
 
Report Parameters Details of Parameter
Market Size xx Million
Based Year 2020
Forecast Period Covered 2020 – 2028
Units for value Revenue in USD million and CAGR from 2020 to 2028
Covered Segments Component, Types, Applications, End-Users, and more.
Companies Covered Zydus Pharmaceuticals, Inc., Tagi Pharma, Inc., Intercept Pharmaceuticals, Inc., ALLERGAN, Amneal Pharmaceuticals LLC, Mylan N.V, Lannett, Hikma Pharmaceuticals PLC, Gemini Pharmaceuticals., Bristol-Myers Squibb Company
Region Covered North America, Europe, Asia Pacific, Latin America, Middle East and Africa

COVID-19 Coverage
With the beginning of the COVID-19 pandemic in early 2020, all major economies around the world enforced severe lockdown restrictions to curb the spread of the virus. Apart from a few sectors such as healthcare and related essential services, most of the industries suffered tremendously due to inability to function in a normal fashion. Moreover, even some of the essential sectors suffered due to delays caused by supply chain disruptions and other travel complexities. However, with massive vaccination drives in most of the developed economies, some of the economies across the world experienced economic recovery from 2021. The Primary Biliary Cholangitis market is expected to gain momentum in such economies and probably recover some of the losses inflicted in the year 2020. With continued efforts towards curbing the virus in the developing economies, the Primary Biliary Cholangitis market is expected to attain Pre COVID-19 levels by mid-2022.

Primary Biliary Cholangitis Report’s Assessment
The research report is formulated such that it offers a deep understating on the market drivers that are assimilating the growth of the market, the market opportunities that are going to provide future growth factors for the market and the market restraints which showcase the reasons as to why the market can get hampered and dissimilated. All these factors are considered keeping in view the historic and forecast analysis which can enlighten the above mentioned factors.

Thereby at a glance a reader can understand all the factors and prospects of the Primary Biliary Cholangitis market and how it can assimilate and dissimilate based on each of the factors and figures mentioned in the report

Primary Biliary Cholangitis Market Competitive and Premeditated Analysis
In the Primary Biliary Cholangitis report major factors such latest tactical developments, competitors, research and development, participation of each region in the market and the competition among them, the latest news regarding company acquisitions and product launch, revenue of the competitors as well as the key offerings they provide all these factors are mentioned in the report with reasons to justify and understand them in depth.

The readers and purchaser of the Primary Biliary Cholangitis research report can gain a comprehensive understanding of the market competition, the revenue of each major players and their contribution towards the market, attractive proposition analysis is provided in the report which sub divides the segments with respect to the largest segment that has contributed to the market growth and the fastest growing segment based on the size of the market as well as its overall appeal.
 
Major Key Players for Global Primary Biliary Cholangitis Market:
The Primary Biliary Cholangitis market research report offers the company profile of major key players including progress trends, competitive landscape breakdown, and key in regions development status. Zydus Pharmaceuticals, Inc., Tagi Pharma, Inc., Intercept Pharmaceuticals, Inc., ALLERGAN, Amneal Pharmaceuticals LLC, Mylan N.V, Lannett, Hikma Pharmaceuticals PLC, Gemini Pharmaceuticals., Bristol-Myers Squibb Company

The Primary Biliary Cholangitis market report showcases vast potentials of growth and assimilation which is going to provide the industry numerous opportunities to grow and generate revenue by understanding the segments and which segment is a potential part to increase the disposable income in the present and upcoming years.

Primary Biliary Cholangitis Market Segmentation Analysis:
Each of the segment is explained in brief along with the revenue it generates for the market based on the historic and forecast data by highlighting the largest segment and the fastest growing segment with reasons to justify it.

The Global segmentation of the Primary Biliary Cholangitis market:
By Treatment Type
Drugs
Liver Transplantation
Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Regional Analysis of the Primary Biliary Cholangitis market:
The Primary Biliary Cholangitis market is dived based on different regions such as North America, Europe, Asia Pacific, Latin America and the Middle East and Africa. And the analysis of each region is provided by highlighting the largest contribution region, the fastest growing region and the factors that is keeping the market active in the other regions is also mentioned in depth. Each regional segment also comprises of the revenue each segment holds in a specific region with reasons to justify the values.

By Regions:
  • North America (U.S and Canada)
  • Europe (U.K., Germany and France)
  • Asia Pacific (China, India and Japan)
  • Latin America (Mexico and Brazil)
  • Middle East and Africa (GCC Countries and South Africa)
 


Major Factors Included and highlighted in the Primary Biliary Cholangitis report are as follows:
  • The overall market value along with historic and future data analysis.
  • The Growth drivers, opportunities and restraints are mention in detail.
  • The size of the entire Primary Biliary Cholangitis market on a global perspective.
  • The CAGR value of the overall market from 2020 to 2028.
  • COVID-19 impact on the Primary Biliary Cholangitis market and how it is coping up with the situation.
  • Major competitors and their contribution towards the market.
  • The segmentation analysis is included which provides a clear picture of the market bifurcation.
  • Tables and graphs that can easily been understood at a glance
  • Latest trends and news related to the Primary Biliary Cholangitis market is included in the report.
Key Analytical Areas:
The report aims to offer a complete solution to various businesses operating in the Primary Biliary Cholangitis market in making strategic decisions based on credible information and actionable insights. Thereby, the report covers various aspects of your requirements such as industry overview, market dynamics, regional analysis and competitive landscape. The report aims to provide insights to businesses in the Primary Biliary Cholangitis market for numerous purposes such as:

     1. Strategic Decision Making:
With the help of this report, key decision makers can quickly analyze and identify growth opportunities in terms of numerous segments across various geographical regions. Thereby, this report enables organizations to identify and make strategic investments in specific market segments in order to gain maximum return on investment.

     2. Actionable Insights:
The report offers a deep dive into how companies are leveraging market conditions to make the most in the Primary Biliary Cholangitis market. Thereby, the report offers numerous actionable insights into the best practices and key success factors relevant in the Primary Biliary Cholangitis market. Using the insights included in the report, businesses can make quick decisions to achieve success in business operations.

     3. Competitive Snapshot:
In addition, to detailed information on the companies operating in the Primary Biliary Cholangitis market, the report also includes a competitive snapshot of all the companies covered in the report. Thereby, this offers a visual representation of how all the companies stand comparatively based on their competencies, geographic presence, market hold, years of operations, employee and financial strength, among others.

Manufacturers and Segments

  • Zydus Pharmaceuticals, Inc.
  • Tagi Pharma, Inc.
  • Intercept Pharmaceuticals, Inc.
  • ALLERGAN
  • Amneal Pharmaceuticals LLC
  • Mylan N.V
  • Lannett
  • Hikma Pharmaceuticals PLC
  • Gemini Pharmaceuticals.
  • Bristol-Myers Squibb Company
  • Drugs
  • Liver Transplantation
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Have query on this report?

Make an Enquiry
1. Preface
     1.1. Report Scope and Description
     1.2. Research Methodology
          1.2.1. Phase I-Secondary Research
          1.2.2. Phase II-Primary Research
          1.2.3. Phase II-Expert Panel Review
          1.2.4. Assumptions
          1.2.5. Approach Adopted

2. Executive Summarysegment Form
     2.1. Global Primary Biliary Cholangitis Market Snapshot
          2.1.1. Global Primary Biliary Cholangitis Market By Treatment Type,2019
               2.1.1.1.Drugs
               2.1.1.2.Liver Transplantation
          2.1.2. Global Primary Biliary Cholangitis Market By Distribution Channel,2019
               2.1.2.1.Hospital Pharmacies
               2.1.2.2.Retail Pharmacies
               2.1.2.3.Online Pharmacies
          2.1.3. Global Primary Biliary Cholangitis Market By End-use,2019
          2.1.4. Global Primary Biliary Cholangitis Market By Geography,2019

3. Global Primary Biliary Cholangitis Market Dynamics
     3.1. Market Overview
     3.2. Market Inclination Insights Analysis
     3.3. Drivers
     3.4. Challenges
     3.5. Future Prospects
     3.6. Impact Analysis of Drivers and Challenges During the Forecast Period, (2020-2028)

4. Global Primary Biliary Cholangitis Market Size (US$), By Treatment Type, 2018 – 2028 
     4.1. Overview
          4.1.1. Market Share Analysis By Treatment Type, 2019 vs.2028
          4.1.2. Attractive Investment Proposition By Treatment Type, 2020
     4.2. Global Primary Biliary Cholangitis Market Size (US$), By Treatment Type, 2018 – 2028

5. Global Primary Biliary Cholangitis Market Size (US$), By Distribution Channel, 2018 – 2028 
     5.1. Overview
          5.1.1. Market Share Analysis By Distribution Channel, 2019 vs.2028
          5.1.2. Attractive Investment Proposition By Distribution Channel, 2020
     5.2. Global Primary Biliary Cholangitis Market Size (US$), By Distribution Channel, 2018 – 2028

6. Global Primary Biliary Cholangitis Market Size (US$), By End-use, 2018 – 2028 
     6.1. Overview
          6.1.1. Market Share Analysis By End-use, 2019 vs.2028
          6.1.2. Attractive Investment Proposition By End-use, 2020
     6.2. Global Primary Biliary Cholangitis Market Size (US$), By End-use, 2018 – 2028

7. Global Primary Biliary Cholangitis Market Size (US$), By Geography, 2018 – 2028
     7.1. Overview
          7.1.1. Market Share Analysis by Geography, 2019 vs. 2028
          7.1.2. Attractive Investment Proposition by Geography, 2020
     7.2. North America Primary Biliary Cholangitis Market Analysis, 2018 – 2028 
          7.2.1. North America Primary Biliary Cholangitis Market Size (US$), By Country, 2018 – 2028 
               7.2.1.1. U.S.
               7.2.1.2. Canada
          7.2.2. North America Primary Biliary Cholangitis Market Size (US$), By Treatment Type, 2018 – 2028
          7.2.3. North America Primary Biliary Cholangitis Market Size (US$), By Distribution Channel, 2018 – 2028
          7.2.4. North America Primary Biliary Cholangitis Market Size (US$), By End-use, 2018 – 2028
     7.3. Europe Primary Biliary Cholangitis Market Analysis, 2018 – 2028 
          7.3.1.  Europe Primary Biliary Cholangitis Market Size (US$), By Country, 2018 – 2028 
               7.3.1.1. U.K.
               7.3.1.2. Germany
               7.3.1.3. France
               7.3.1.4. Rest of Europe
          7.3.2. Europe Primary Biliary Cholangitis Market Size (US$), By Treatment Type, 2018 – 2028
          7.3.3. Europe Primary Biliary Cholangitis Market Size (US$), By Distribution Channel, 2018 – 2028
          7.3.4. Europe Primary Biliary Cholangitis Market Size (US$), By End-use, 2018 – 2028
     7.4. Asia Pacific Primary Biliary Cholangitis Market Analysis , 2018 – 2028
          7.4.1.  Asia Pacific Primary Biliary Cholangitis Market Size (US$), By Country, 2018 – 2028 
               7.4.1.1. China
               7.4.1.2. Japan
               7.4.1.3. India
               7.4.1.4. Rest of Asia Pacific
          7.4.2. Asia Pacific Primary Biliary Cholangitis Market Size (US$), By Treatment Type, 2018 – 2028
          7.4.3. Asia Pacific Primary Biliary Cholangitis Market Size (US$), By Distribution Channel, 2018 – 2028
          7.4.4. Asia Pacific Primary Biliary Cholangitis Market Size (US$), By End-use, 2018 – 2028
     7.5. Latin America Primary Biliary Cholangitis Market Analysis, 2018 – 2028 
          7.5.1.  Latin America Primary Biliary Cholangitis Market Size (US$), By Country, 2018 – 2028 
               7.5.1.1. Brazil
               7.5.1.2. Mexico
               7.5.1.3. Rest of Latin America
          7.5.2. Latin America Primary Biliary Cholangitis Market Size (US$), By Treatment Type, 2018 – 2028
          7.5.3. Latin America Primary Biliary Cholangitis Market Size (US$), By Distribution Channel, 2018 – 2028
          7.5.4. Latin America Primary Biliary Cholangitis Market Size (US$), By End-use, 2018 – 2028
     7.6. Middle East & Africa (MEA) Primary Biliary Cholangitis Market Analysis, 2018 – 2028 
          7.6.1.  MEA Primary Biliary Cholangitis Market Size (US$), By Region, 2018 – 2028 
               7.6.1.1. GCC Countries
               7.6.1.2. South Africa
               7.6.1.3. Rest of MEA
          7.6.2. MEA Primary Biliary Cholangitis Market Size (US$), By Treatment Type, 2018 – 2028
          7.6.3. MEA Primary Biliary Cholangitis Market Size (US$), By Distribution Channel, 2018 – 2028
          7.6.4. MEA Primary Biliary Cholangitis Market Size (US$), By End-use, 2018 – 2028

8. Company Profiles
     8.1. Competitive Analysis 
     8.2. Market Positioning of Key Vendors 
     8.3. Key Strategies adopted by the Leading Players
     8.4. Key Primary Biliary Cholangitis Providers
        8.4.1 Zydus Pharmaceuticals, Inc.
                8.4.1.1 Business Description
                8.4.1.2 Zydus Pharmaceuticals, Inc. Geographic Operations
                8.4.1.3 Zydus Pharmaceuticals, Inc. Financial Information
                8.4.1.4 Zydus Pharmaceuticals, Inc. Product Positions/Portfolio
                8.4.1.5 Zydus Pharmaceuticals, Inc. Key Developments
        8.4.2 Tagi Pharma, Inc.
                8.4.2.1 Business Description
                8.4.2.2 Tagi Pharma, Inc. Geographic Operations
                8.4.2.3 Tagi Pharma, Inc. Financial Information
                8.4.2.4 Tagi Pharma, Inc. Product Positions/Portfolio
                8.4.2.5 Tagi Pharma, Inc. Key Developments
        8.4.3 Intercept Pharmaceuticals, Inc.
                8.4.3.1 Business Description
                8.4.3.2 Intercept Pharmaceuticals, Inc. Geographic Operations
                8.4.3.3 Intercept Pharmaceuticals, Inc. Financial Information
                8.4.3.4 Intercept Pharmaceuticals, Inc. Product Positions/Portfolio
                8.4.3.5 Intercept Pharmaceuticals, Inc. Key Developments
        8.4.4 ALLERGAN
                8.4.4.1 Business Description
                8.4.4.2 ALLERGAN Geographic Operations
                8.4.4.3 ALLERGAN Financial Information
                8.4.4.4 ALLERGAN Product Positions/Portfolio
                8.4.4.5 ALLERGAN Key Developments
        8.4.5 Amneal Pharmaceuticals LLC
                8.4.5.1 Business Description
                8.4.5.2 Amneal Pharmaceuticals LLC Geographic Operations
                8.4.5.3 Amneal Pharmaceuticals LLC Financial Information
                8.4.5.4 Amneal Pharmaceuticals LLC Product Positions/Portfolio
                8.4.5.5 Amneal Pharmaceuticals LLC Key Developments
        8.4.6 Mylan N.V
                8.4.6.1 Business Description
                8.4.6.2 Mylan N.V Geographic Operations
                8.4.6.3 Mylan N.V Financial Information
                8.4.6.4 Mylan N.V Product Positions/Portfolio
                8.4.6.5 Mylan N.V Key Developments
        8.4.7 Lannett
                8.4.7.1 Business Description
                8.4.7.2 Lannett Geographic Operations
                8.4.7.3 Lannett Financial Information
                8.4.7.4 Lannett Product Positions/Portfolio
                8.4.7.5 Lannett Key Developments
        8.4.8 Hikma Pharmaceuticals PLC
                8.4.8.1 Business Description
                8.4.8.2 Hikma Pharmaceuticals PLC Geographic Operations
                8.4.8.3 Hikma Pharmaceuticals PLC Financial Information
                8.4.8.4 Hikma Pharmaceuticals PLC Product Positions/Portfolio
                8.4.8.5 Hikma Pharmaceuticals PLC Key Developments
        8.4.9 Gemini Pharmaceuticals.
                8.4.9.1 Business Description
                8.4.9.2 Gemini Pharmaceuticals. Geographic Operations
                8.4.9.3 Gemini Pharmaceuticals. Financial Information
                8.4.9.4 Gemini Pharmaceuticals. Product Positions/Portfolio
                8.4.9.5 Gemini Pharmaceuticals. Key Developments
        8.4.10 Bristol-Myers Squibb Company
                8.4.10.1 Business Description
                8.4.10.2 Bristol-Myers Squibb Company Geographic Operations
                8.4.10.3 Bristol-Myers Squibb Company Financial Information
                8.4.10.4 Bristol-Myers Squibb Company Product Positions/Portfolio
                8.4.10.5 Bristol-Myers Squibb Company Key Developments

LIST OF TABLES

TABLE 1 Market Snapshot: Global Primary Biliary Cholangitis Market 
TABLE 2 Impact Indicators 
TABLE 3 Impact Analysis of Drivers and Restraints 
TABLE 4 North America Primary Biliary Cholangitis Market Revenue, By Treatment Type, 2018 – 2028 (US$ Mn) 
TABLE 5 North America Primary Biliary Cholangitis Market Revenue, By Distribution Channel, 2018 – 2028 (US$ Mn) 
TABLE 6 North America Primary Biliary Cholangitis Market Revenue, By End-use, 2018 – 2028 (US$ Mn) 
TABLE 7 Europe Primary Biliary Cholangitis Market Revenue, By Treatment Type, 2018 – 2028 (US$ Mn) 
TABLE 8 Europe Primary Biliary Cholangitis Market Revenue, By Distribution Channel, 2018 – 2028 (US$ Mn) 
TABLE 9 Europe Primary Biliary Cholangitis Market Revenue, By End-use, 2018 – 2028 (US$ Mn) 
TABLE 10 Asia Pacific Primary Biliary Cholangitis Market Revenue, By Treatment Type, 2018 – 2028 (US$ Mn) 
TABLE 11 Asia Pacific Primary Biliary Cholangitis Market Revenue, By Distribution Channel, 2018 – 2028 (US$ Mn) 
TABLE 12 Asia Pacific Primary Biliary Cholangitis Market Revenue, By End-use, 2018 – 2028 (US$ Mn) 
TABLE 13 Latin America Primary Biliary Cholangitis Market Revenue, By Treatment Type, 2018 – 2028 (US$ Mn) 
TABLE 14 Latin America Primary Biliary Cholangitis Market Revenue, By Distribution Channel, 2018 – 2028 (US$ Mn) 
TABLE 15 Latin America Primary Biliary Cholangitis Market Revenue, By End-use, 2018 – 2028 (US$ Mn)
TABLE 16 MEA Primary Biliary Cholangitis Market Revenue, By Treatment Type, 2018 – 2028 (US$ Mn) 
TABLE 17 MEA Primary Biliary Cholangitis Market Revenue, By Distribution Channel, 2018 – 2028 (US$ Mn) 
TABLE 18 MEA Primary Biliary Cholangitis Market Revenue, By End-use, 2018 – 2028 (US$ Mn)

LIST OF FIGURES

FIG. 1 Global Primary Biliary Cholangitis: Market Segmentation 
FIG. 2 Global Primary Biliary Cholangitis Market: Research Methodology 
FIG. 3 Top-Down and Bottom-up Approach 
FIG. 4 Global Primary Biliary Cholangitis Market, By Treatment Type, 2019 (US$ Mn) 
FIG. 5 Global Primary Biliary Cholangitis Market, By Distribution Channel, 2019 (US$ Mn) 
FIG. 6 Global Primary Biliary Cholangitis Market, By End-use, 2019 (US$ Mn) 
FIG. 7 Global Primary Biliary Cholangitis Market, By Geography, 2019 (US$ Mn) 
FIG. 8 Global Primary Biliary Cholangitis Market Revenue and Growth, 2018 – 2028, (US$ Mn) (Y-o-Y %)
FIG. 9 Attractive Investment Proposition 
FIG. 10 Market Positioning of Key Primary Biliary Cholangitis Providers, 2019
FIG. 11 Global Primary Biliary Cholangitis Market Revenue Contribution, By Treatment Type, 2019 & 2028 (Value %) 
FIG. 12 Global Primary Biliary Cholangitis Market Revenue Contribution, By Distribution Channel, 2019 & 2028 (Value %) 
FIG. 13 Global Primary Biliary Cholangitis Market Revenue Contribution, By End-use, 2019 & 2028 (Value %) 
FIG. 14 North America Primary Biliary Cholangitis Market Revenue, 2018 – 2028, (US$ Mn) 
FIG. 15 Europe Primary Biliary Cholangitis Market Revenue, 2018 – 2028, (US$ Mn) 
FIG. 16 Asia Pacific Primary Biliary Cholangitis Market Revenue, 2018 – 2028, (US$ Mn) 
FIG. 17 Latin America Primary Biliary Cholangitis Market Revenue, 2018 – 2028, (US$ Mn)
FIG. 18 MEA Primary Biliary Cholangitis Market Revenue, 2018 – 2028, (US$ Mn)

Key Takeaways:

1. Market value and estimate of the Primary Biliary Cholangitis market for the period from 2020 to 2028
2. Compounded annual growth rate (CAGR%) for individual segments in various regional markets for a period from 2020 to 2028
3. Value chain analysis
4. Market share study combined with competitive landscape of major players
5. Profiles of major market players covering overall business operations, geographic occurrence, product portfolio, financial status and news coverage 

List of Tables

TABLE  Market Snapshot: Global Primary Biliary Cholangitis Market
TABLE  Impact Pointers
TABLE  Impact Analysis of Drivers and Restraints
TABLE  North America Primary Biliary Cholangitis Market Value, By Segment1, 2018 – 2028
TABLE  North America Primary Biliary Cholangitis Market Value, By Segment2, 2018 – 2028
TABLE  North America Primary Biliary Cholangitis Market Value, By Country, 2018 – 2028
TABLE  Europe Primary Biliary Cholangitis Market Value, By Segment1, 2018 – 2028
TABLE  Europe Primary Biliary Cholangitis Market Value, By Segment2, 2018 – 2028
TABLE  Europe Primary Biliary Cholangitis Market Value, By Country, 2018 – 2028
TABLE  Asia Pacific Primary Biliary Cholangitis Market Value, By Segment1, 2018 – 2028
TABLE  Asia Pacific Primary Biliary Cholangitis Market Value, By Segment2, 2018 – 2028
TABLE  Asia Pacific Primary Biliary Cholangitis Market Value, By Country, 2018 – 2028
TABLE  Latin America Primary Biliary Cholangitis Market Value, By Segment1, 2018 – 2028
TABLE  Latin America Primary Biliary Cholangitis Market Value, By Segment2, 2018 – 2028
TABLE  Latin America Primary Biliary Cholangitis Market Value, By Country, 2018 – 2028
TABLE  MEA Primary Biliary Cholangitis Market Value, By Segment1, 2018 – 2028
TABLE  MEA Primary Biliary Cholangitis Market Value, By Segment2, 2018 – 2028
TABLE  MEA Primary Biliary Cholangitis Market Value, By Country, 2018 – 2028
TABLE  Zydus Pharmaceuticals, Inc.: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Tagi Pharma, Inc.: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Intercept Pharmaceuticals, Inc.: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  ALLERGAN: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Amneal Pharmaceuticals LLC: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Mylan N.V: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Lannett: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Hikma Pharmaceuticals PLC: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Gemini Pharmaceuticals.: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Bristol-Myers Squibb Company: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
 

List of Figures

FIG.  Global Primary Biliary Cholangitis Market: Research Methodology
FIG.  Top-Down and Bottom Up Approach
FIG.  Global Primary Biliary Cholangitis Market, By Segment1, 2019 (US$ Mn)
FIG.  Global Primary Biliary Cholangitis Market, By Segment2, 2019 (US$ Mn)
FIG.  Global Primary Biliary Cholangitis Market, By Geography, 2019 (US$ Mn)
FIG.  Global Primary Biliary Cholangitis Market Value and Growth, 2018 – 2028, (US$ Mn) (Y-o-Y %)
FIG.  Attractive Investment Proposition
FIG.  Market Positioning of Key Primary Biliary Cholangitis Providers, 2016
FIG.  Global Primary Biliary Cholangitis Market Value Share, By Segment1, 2019 & 2028 (% Value)
FIG.  Global Liver Transplantation Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Primary Biliary Cholangitis Market Value Share, By Segment2, 2019 & 2028 (% Value)
FIG.  Global Retail Pharmacies Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Online Pharmacies Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Market Value, 2018 – 2028, (US$ Mn)
FIG.  U.S. Primary Biliary Cholangitis Market Value, 2018 – 2028, (US$ Mn)
FIG.  Canada Primary Biliary Cholangitis Market Value, 2018 – 2028, (US$ Mn)
FIG.  UK Primary Biliary Cholangitis Market Value, 2018 – 2028, (US$ Mn)
FIG.  Germany Primary Biliary Cholangitis Market Value, 2018 – 2028, (US$ Mn)
FIG.  France Primary Biliary Cholangitis Market Value, 2018 – 2028, (US$ Mn)
FIG.  Rest of Europe Primary Biliary Cholangitis Market Value, 2018 – 2028, (US$ Mn)
FIG.  China Primary Biliary Cholangitis Market Value, 2018 – 2028, (US$ Mn)
FIG.  Japan Primary Biliary Cholangitis Market Value, 2018 – 2028, (US$ Mn)
FIG.  India Primary Biliary Cholangitis Market Value, 2018 – 2028, (US$ Mn)
FIG.  Rest of Asia Pacific Primary Biliary Cholangitis Market Value, 2018 – 2028, (US$ Mn)
FIG.  Mexico Primary Biliary Cholangitis Market Value, 2018 – 2028, (US$ Mn)
FIG.  Brazil Primary Biliary Cholangitis Market Value, 2018 – 2028, (US$ Mn)
FIG.  Rest of Latin America Primary Biliary Cholangitis Market Value, 2018 – 2028, (US$ Mn)
FIG.  GCC Countries Primary Biliary Cholangitis Market Value, 2018 – 2028, (US$ Mn)
FIG.  South Africa Primary Biliary Cholangitis Market Value, 2018 – 2028, (US$ Mn)
FIG.  Rest of MEA Primary Biliary Cholangitis Market Value, 2018 – 2028, (US$ Mn)